Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception

• Status: Unknown status
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to evaluate the contraceptive efficacy and safety of an oral contraceptive containing a combination of LNG 100mcg/EE 20mcg compared to LNG 150mcg/EE 30 mcg.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Regenex Pharmaceutical, China
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Ethinyl Estradiol; Ethinyl estradiol, levonorgestrel drug combination; Levonorgestrel; Polyestradiol phosphate

Criteria

Inclusion Criteria:

• Healthy women,aged 20-35 years who wish to use a contraceptive.

• Women without reproductive system infection complications.

• Willingness to not use other forms of hormonal treatment.

• Three regular menstrual cycles before the study(21-35 days per cycle with 3-7 day's bleeding period, without amenorrhea or irregular bleeding).

• Signed informed consent prior to entry into the trial.

Exclusion Criteria:

• Any contraindication to the use of oral contraceptives.

• Vascular, metabolic, hepatic, renal, oncologic and other diseases.